Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Fulcrum Therapeutics ( (FULC) ) has provided an announcement.
Fulcrum Therapeutics announced that Genzyme Corporation, a Sanofi subsidiary, has chosen to terminate their collaboration and license agreement regarding the commercialization of losmapimod for facioscapulohumeral muscular dystrophy outside the United States. This termination, effective April 17, 2025, will halt milestone payments, royalties, and shared global development costs, impacting Fulcrum’s financial and operational expectations. Until then, both parties will continue fulfilling their obligations under the agreement.
More about Fulcrum Therapeutics
Fulcrum Therapeutics operates in the biotechnology industry, focusing on the development of treatments for genetically defined diseases. The company is primarily engaged in researching and commercializing small molecule therapies, with a particular focus on muscle disorders.
YTD Price Performance: -35.56%
Average Trading Volume: 1,005,350
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $234.6M
Find detailed analytics on FULC stock on TipRanks’ Stock Analysis page.